Quinapril is a potent, orally active, non-peptide and nonsulfhydryl inhibitor of angiotensin-converting enzyme (ACE). Quinapril specifically interrupts the conversion of angiotensin I to angiotensin II in both plasma and tissue. Quinapril is enzymatically hydrolyzed to a pharmacologically active diacid form quinaprilat. Quinapril is efficacious in hypertensive models.

Perindopril L-arginine is an orally active and selective angiotensin-converting enzyme (ACE) inhibitor. Perindopril L-arginine reduces the production of angiotensin II by inhibiting ACE, thereby dilating blood vessels, lowering blood pressure, and also exerting activities such as vasculoprotection and antithrombosis. Perindopril L-arginine is promising for research of cardiovascular diseases.

AD015 is a angiotensin-converting enzyme (ACE) and neprilysin (NEP) dual inhibitor. AD015 inhibits NEP, nACE and cACE with IC50s of 0.009, 0.019 and 0.0008 μM, respectively.

SDUY816 is an oral active dual APN/NEP inhibitor, with IC50 values of 0.68 μM for APN and 6.9 μM for NEP. SDUY816 exhibits analgesic effects and demonstrates good safety and pharmacokinetic profiles, with an oral bioavailability of 27% and a half-life of 4.02 hours in rats (oral administration, 10 mg/kg). SDUY816 has potential applications in the research of neuropathic pain disorders.

LYS006 hydrochloride is a potent inhibitor of leukotriene A4 hydrolase (LTA4H) extracted from patent WO2015092740A1, example 29, has an IC50 of 2 nM. LYS006 hydrochloride can be used for the research of inflammatory and autoimmune disorders.

DG013B formate is an epimer of DG013A.

DG013B is an epimer of DG013A.

DG013A (formate) is a phosphinic acid tripeptide mimetic inhibitor. DG013A (formate) displays significantly weak affinity for both ERAP1 (IC50=33 nM) and ERAP2 (IC50=11 nM). DG013A (formate) can be used for the research of autoimmune disease and cancer.

BDM_92499 is a nanomolar selective IRAP inhibitor, with an IC50 of 3.4 nM. BDM_92499 also inhibits ERAP1 and ERAP2, with IC50 values of 0.46 μM and 4.2 μM, respectively.

Arphamenine A is an aminopeptidase B inhibitor found in Chromobacteriuin violaceum HMG361-CF4. Arphamenine A can inhibit the activity of aminopeptidase B, and can inhibit sarcoma 180 and invasive micropapillary carcinoma (IMC) cancer.

Apstatin TFA is a potent aminopeptidase P (APP) inhibitor with Ki values of 2.6, 0.64 µM for rat and human APP, respectively. Apstatin TFA shows cardioprotection.

WF-3681 (compound 1) is an aldose reductase inhibitor and a fungal metabolite.

RJG-2051 is a selective covalent aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor with an IC50 value of 13 nM. RJG-2051 interferes with the metabolic process of substrates such as androgens, estrogens, and prostaglandins by AKR1C3. RJG-2051 is promising for research of cancers.

M79175 is an aldose reductase inhibitor that can be used in the study of early diabetic retinopathy.

(Rac)-Fidarestat ((Rac)-SNK 860) is the racemate of Fidarestat-resistant hepatitis B.

Mirivadelgat is an activator of aldehyde dehydrogenase 2 activator. Mirivadelgat is promising for research of interstitial lung disease-pulmonary hypertension and cancers.

DG 381B (compound 62) is a 11β-HSD1 and 11β-HSD2inhibitor.

ZQMT-10 is an orally active and potent antagonist of TRPA1, with the Kd of 1.04 μM. ZQMT-10 plays an important role in cancer research.

Davasaicin (KR 25018), Capsaicin derivative and a δ-opioid receptor agonist. AZ 12488024 is available for research into major depressive disorder.

CMP233 is a potent antagonist of TRPM4, with the IC50 of 0.15 μM. CMP233 plays an important role in neurodegenerative disorders research.

(S)-AMG-628 (Compound 16q) is the S-isomer of AMG-628. (S)-AMG-628 is the orally active antagonist for TRPV1, that inhibits the Capsaicin- and acid-induced Ca2+-influx with IC50 of 7 nM and 5 nM in CHO cell. (S)-AMG-628 ameliorates Capsaicin-induced rats flinching, and reverses the thermal hypersensitivity in CFA-induced inflammatory pain models.

Zilvetrigine is a sodium channel blocker. Zilvetrigine can be used as analgesics.

Quinacainol dihydrochloride (PK 10139 dihydrochloride) is the dihydrochloride salt form of Quinacainol.

Olisutrigine bromide is a sodium channel blocker, which can be used as analgesics.

N-Hydroxy riluzole is a metabolite of the antiglutamatergic agent Riluzole.

ETD001 is a long-acting ENaC inhibitor, with an IC50 of 57.5 nM in cultured HBE cells. ETD001 can be used in the study for cystic fibrosis.

ErSO-TFPy activates the sodium channel TRPM4, causes an imbalance of intracellular calcium and sodium ions. ErSO-TFPy exhibits low nanomolar cytotoxicity in ERα+ breast cancer cell lines (IC50 = 5-25 nM) through induction of necrosis. ErSO-TFPy exhbits antitumor efficacy in mouse models.

DAPI (Compound 3) is an acid-sensing ion channel 3 (ASIC3) inhibitor. DAPI binds to ASIC3 and blocks the channel function. DAPI can be used in the study of chronic pain treatment.

CL-424032 is a sodium channel inhibitor.

CAY10568 is a compound based on QX-314 and a linker. MC-PEG2-VA-PAB-Exatecan can be used for synthesis of ADCs.